naratriptan 2.5 mg

1 INDICATIONS AND USAGE Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets, reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. Naratriptan tablets are a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. (1) Limitations of Use: Use only if a clear diagnosis of migraine has been established. (1) Not indicated for the prophylactic therapy of migraine attacks. (1) Not indicated for the treatment of cluster headache. (1)

a-s medication solutions

FDA Reported Adverse Reactions
`[1] fatigue` `[2] drug ineffective` `[3] dyspnoea` `[4] pain` `[5] abdominal discomfort` `[6] alopecia` `[7] off label use` `[8] headache` `[9] rheumatoid arthritis` `[10] systemic lupus erythematosus`

2 years ago

OVAL GREEN N 2 5

2 years ago

N 2 5 OVAL GREEN

16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-6162 NDC: 50090-6162-0 9 TABLET, film coated in a BLISTER PACK / 1 in a CARTON

More pills like OVAL N 2 5

Related Pills

lisinopril 2.5 mg

lupin pharmaceuticals, inc.

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site